Talphera (TLPH) EBT Margin (2011 - 2025)

Talphera (TLPH) posted quarterly EBT Margin of 356700.0% for Q3 2025, down 3282.82% quarter-over-quarter from 10544.44% in Q1 2025.

Talphera (TLPH) EBT Margin (2011 - 2025) Analysis & Trends

Talphera's EBT Margin history runs 14 years deep, the most recent figure standing at 356700.0% for Q3 2025.

In Q3 2025, EBT Margin changed N/A year-over-year to 356700.0%; the TTM figure through Mar 2026 stood at 8681100.0% (down 863250741.0% YoY), while the FY2025 annual figure was 305482.14%, changed N/A from the prior year.
EBT Margin for Q3 2025 stood at 356700.0%, down from 10544.44% in the prior quarter.
The five-year high for EBT Margin was 65.67% in Q1 2023, with the low at 395850.0% in Q4 2021.
The 4-year median for EBT Margin is 1905.68% (2021), against an average of 70405.66%.
Peak annual rise in EBT Margin reached 243837 bps in 2021, while the deepest fall reached 39464160 bps in 2021.
Talphera's EBT Margin stood at 395850.0% in 2021, then soared by 99 bps to 2116.97% in 2022, then gained by 24 bps to 1604.98% in 2023, then sank by 22125 bps to 356700.0% in 2025.
Business Quant data shows TLPH's EBT Margin at 356700.0% in Q3 2025, 10544.44% in Q1 2025, and 1604.98% in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn	-10.99%
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	13.34%
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn	47.58%
6	Viatris	18.68 Bn	17.79 Bn	1.46 Bn	-1.70%
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	16.91%
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	4.09%
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Talphera	89.95 Mn	89.95 Mn	-	-

Download Data